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Abstract 
Background: Severely ill patients might develop an alteration of their immune system called post‑aggressive immu‑
nosuppression. We sought to assess the risk of ICU‑acquired infection and of mortality according to the absolute 
lymphocyte count at ICU admission and its changes over 3 days.
Methods: Adults in ICU for at least 3 days with a shock or persistent low blood pressure were extracted from a French 
ICU database and included. We evaluated the impact of the absolute lymphocyte count at baseline and its change at 
day 3 on the incidence of ICU‑acquired infection and on the 28‑day mortality rate. We categorized lymphocytes in 4 
groups: above 1.5 × 103 cells/µL; between 1 and 1.5 × 103 cells/µL; between 0.5 and 1 × 103 cells/µL; and below 0.5 
× 103 cells/µL.
Results: A total of 753 patients were included. The median lymphocyte count was 0.8 × 103 cells/µL [0.51–1.29]. A 
total of 174 (23%) patients developed infections; the 28‑day mortality rate was 21% (161/753). Lymphopenia at admis‑
sion was associated with ICU‑acquired infection (p < 0.001) but not with 28‑day mortality. Independently of baseline 
lymphocyte count, the absence of lymphocyte count increase at day 3 was associated with ICU‑acquired infection 
(sub‑distribution hazard ratio sHR: 1.37 [1.12–1.67], p = 0.002) and with 28‑day mortality (sHR: 1.67 [1.37–2.03], p < 
0.0001).
Conclusion: Lymphopenia at ICU admission and its persistence at day 3 were associated with an increased risk 
of ICU‑acquired infection, while only persisting lymphopenia predicted increased 28‑day mortality. The lympho‑
cyte count at ICU admission and at day 3 could be used as a simple and reproductive marker of post‑aggressive 
immunosuppression.
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Background
Lymphopenia is defined as a decrease below normal 
value (often 1.5 ×  103 cells/µL) of the blood circulating 
lymphocyte count; it reflects an impairment of the adap-
tive immune system. Several diseases can cause lympho-
penia; they are associated with a higher risk of infection 
and adverse outcome [1, 2].
In critically ill patients, especially those with septic 
shock, after an initial phase of immune system hyper-
stimulation, dysfunction could appear secondarily. This 
is often called post-aggressive immunosuppression or 
compensatory anti-inflammatory response syndrome 
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(CARS). It affects the innate and adaptive immune system 
[3, 4]. There is an increase in the level of anti-inflamma-
tory cytokines, e.g., interleukin (IL)-10, in contrast to the 
decrease in pro-inflammatory cytokines levels, such as 
IL-6 or TNF-α. Immune cells are altered in both dimen-
sions, qualitatively, and also quantitatively, as demon-
strated with cells of innate immunity [5–7]. Persistence of 
CARS is associated with the risk of ICU-acquired infec-
tions and adverse outcome [7, 8].
Studies have shown the impact of critical illness on 
lymphocyte apoptosis and anergy [9–12]; however, there 
are few reports about the prognostic value in ICU of total 
lymphocyte count at admission and its evolution. These 
studies often evaluated the association between adverse 
outcome and other biomarkers of lymphocyte dysfunc-
tion than the lymphocyte count. However, the lympho-
cyte count would be a simple and reproducible marker of 
CARS. It was shown that low absolute lymphocyte counts 
are predictive of postoperative sepsis and a better predic-
tor of bacteremia than conventional markers in patients 
admitted in emergency care units [13, 14]. Furthermore, 
a very recent study showed that persistent lymphopenia 
on the fourth day after bacteremia diagnosis predicts 
early and late mortality in those patients, including in the 
subgroup of patients with sepsis [15].
The main objective of this study was to evaluate the risk 
of development of an ICU-acquired infection according 
to the absolute lymphocyte blood count at admission and 
its evolution at day 3. The second objective was to evalu-
ate how these parameters impact the 28-day mortality.
Methods
We performed a retrospective study on data prospec-
tively collected within the cohort study conducted with 
centers participating to the OUTCOMEREA database 
(OutcomeRea®).
Ethical issues
This study was approved by our institutional review 
board (CECIC Clermont-Ferrand—IRB n°5891; Ref: 
2007–2016), which waived the need for signed informed 
consent of the participants, in accordance with French 
legislation on non-interventional studies. However, the 
patients and their next of kin were asked whether they 
were willing to participate in the database, and none 
declined participation.
Data collection
Data were prospectively collected daily by senior physi-
cians in the participating ICUs. For each patient, the 
data were entered into electronic case report forms 
using VIGIREA® and RHEA® data capture software, 
and all case report forms were then entered into the 
OutcomeRea® data warehouse. All codes and defini-
tions were established prior to study initiation. For each 
patient, age, sex, and McCabe score were recorded. 
Severity of illness was evaluated on the first ICU day 
using the Simplified Acute Physiology Score (SAPS II), 
Sequential Organ Failure Assessment (SOFA) score, and 
Glasgow Coma Scale (GCS) score, and Knaus’ scale defi-
nitions were used to record preexisting chronic organ 
failures including respiratory, cardiac, hepatic, renal, and 
immune system failures. Admission category (medical, 
scheduled surgery, or unscheduled surgery), admission 
diagnosis (cardiac, respiratory, or neurological failure, 
infection, and other), invasive procedures (arterial or 
venous central catheter, Swan-Ganz catheter, or endotra-
cheal intubation), and treatment of organ failures (ino-
tropic support, hemodialysis, and mechanical ventilation) 
and the use of corticosteroids, gastro-protective drugs, 
and antibiotics were also recorded. Daily lymphocyte 
counts were retrospectively collected from four ICUs 
participating to OUTCOMEREA database between July 
2006 and May 2012. All patients with a lymphocyte count 
in the first day of admission were included in the study. 
In order to avoid confusion bias, we excluded patients 
with chronic lymphocytic leukemia (CLL), infection with 
the human immunodeficiency virus (HIV) or aplasia at 
admission. We also excluded patients with limitation of 
life-sustaining therapy in the four first days after admis-
sion. Patients with shock or persistent low blood pressure 
below 90 mmHg of systolic blood pressure in the first day 
of admission were included. Study variables were the first 
lymphocyte count on the first day of admission and its 
evolution at day 3 after admission. The lymphocyte count 
at admission was categorized in four predefined classes: 
normal (>1.5 × 103 cells/µL); subnormal (1 × 103 cells/µL 
< lymphocytes ≤1.5 × 103 cells/µL); low (0.5 × 103 cells/
µL < lymphocytes ≤1 ×  103 cells/µL); very low (≤0.5 
× 103 cells/µL).
The evolution of lymphocyte count at day 3 versus 
baseline was defined as a binary variable: normal count 
(≥1.5 ×  103 cells/µL) or relevant increase (more than 
0.2 × 103 cells/µL) and decrease or no relevant increase 
(≤0.2 × 103 cells/µL). We handled missing values at day 
3 (n = 166, 22.1%) by taking the value one day before or 
after.
Nosocomial infection was defined as bacteremia, pneu-
monia, or catheter-related infection occurring after 72  h 
from admission. Definition of nosocomial infection pro-
vided from the HELICS (Hospital in Europe Link for 
Infection Control through Surveillance) project [16]. Bac-
teraemia was defined as the presence of pathogenic bac-
teria in blood culture. Pneumonia was defined as a chest 
X-ray with suggestive image of pneumonia with clinical 
and biological signs of pulmonary infection associated 
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with a positive quantitative bacteriological culture from a 
respiratory sample: a broncho-alveolar lavage [BAL ≥104 
colony-forming unit (CFU)/ml]; a protected specimen 
brush (≥103 CFU/ml); a blind protected bronchial sam-
pling (≥103 CFU/ml); a tracheal aspiration (≥105 CFU/
ml). Catheter infection was defined as positive quantitative 
catheter culture (≥103 CFU/ml) treated by physicians in 
charge. Only the first event was considered for analysis.
Statistical analysis
Characteristics of patients were described as count (per-
cent) or median [interquartile range, IQR] for qualitative 
and quantitative variables, respectively, and were com-
pared between groups using Chi-square or Mann–Whit-
ney tests, as appropriate.
In order to decrease the risk of confusion bias between 
lymphopenia and acquired-ICU infection, we developed 
a propensity score aimed to predict the probability to 
have a nosocomial infection conditionally on variables 
recorded in the first 2 days of admission [17].
A logistic regression was used to construct the pro-
pensity score including variables on clinical relevance or 
statistic comparison on univariate analysis. Linearity of 
the logit of continuous covariates was checked. The fol-
lowing clinically relevant variables were entered in the 
model: age, gender, admission category, center, Knaus 
definitions, McCabe score, main reason for ICU admis-
sion (multi-organ failure, cardiogenic shock, septic 
shock, coma, acute respiratory deficiency), diabetes with 
complications (binary variable), severity illness related 
to specific organ assessed by the sequential SOFA score 
categorized in 2 classes, lower or equal to two or higher 
(cardiovascular, neurological, hepatic, renal, coagulation 
failures), acute respiratory distress syndrome, mechanical 
ventilation, central venous catheter, arterial catheter or 
arterial pulmonary catheter, temperature, use of gastro-
protective drugs, antibiotics, or corticosteroids.
Then, an inverse probability of treatment weighted 
(IPTW) [18] based on the propensity score was com-
puted to create a pseudo-population in which the prob-
ability to develop or not an ICU-acquired infection was 
equal. We performed a model with covariates using for 
the construction of the propensity score weighted by the 
IPTW including the explicative variables, baseline lym-
phocyte count, and evolution at the third day [19]. We 
took the 5–95th percentiles of IPTW to create a new 
pseudo-population to assess the robustness of the model.
Sub-distribution hazard ratios (sHRs) were developed 
to assess the independent effects of lymphocyte count 
at admission and the evolution at day 3 on subsequent 
risk of ICU-acquired infection. Discharge alive from ICU 
was treated as competing events. Data were censored at 
28 days since the fourth day after admission.
For the secondary objective, risk of death related to 
initial lymphocyte count and its evolution at day 3, the 
same protocol was used. We developed a specific pro-
pensity score aiming to predict the probability to die in 
ICU within 28  days of inclusion conditionally on vari-
ables recorded within the first 2 days of admission. The 
following clinically relevant variables were entered in the 
model: age, gender, admission category, center, Knaus 
definitions, cardiogenic shock as symptom at admission, 
continuous monitoring as reason of admission, compli-
cated diabetes, severity illness related to specific organ 
assessed by the SOFA score categorized in two classes, 
lower, or equal to 2 or higher (cardiovascular, neurologi-
cal, hepatic, renal, coagulation failure), respiratory failure 
severity reflected by acute respiratory distress syndrome, 
requiring invasive mechanical ventilation, central venous 
catheter, arterial catheter or arterial pulmonary catheter, 
temperature, use of corticosteroids.
Sub-distribution hazard ratios (sHRs) were developed 
with covariates using for the construction of the propen-
sity score weighted by the IPTW. Discharge alive from 
ICU was treated as competing events. For all analyses, p 
< .05 was considered to statistically significant. All analy-




Of the 2402 patients recorded within the 4 participating 
ICUs (Fig. 1), 753 patients were included. The mean age 
was 68 [56; 78] years, 467 patients (62%) were males, and 
the median SOFA score at admission was 8 [5, 11]. Medi-
cal admission represented the most frequent cases [596 
patients (79%)], and septic shock was the first diagnosis 
at admission in 154 patients (21%). Mechanical ventila-
tion was required for 559 patients (74%) and vasoactive 
agents at day 1 or 2 for 480 patients (63.8%). The median 
length of stay in ICU was 9  days [6–18]. A total of 174 
(23%) patients had ICU-acquired infection and 161 (21%) 
patients died in ICU during the study period (Table 1).
The median number of lymphocyte counts measure-
ments was 6 [4–13]. The percentage of day with a lym-
phocyte count by patient during ICU stay was 75%, and 
the median range between two blood samples with lym-
phocyte count was 1 day. The median of the lymphocyte 
count at admission was 0.80 [0.51–1.29] × 103 cells/µL. 
The distribution in 4 classes was as follows: 149 patients 
(20%) had a normal lymphocyte count with a median of 
1.97 [1.70–2.80] × 103 cells/µL; 141 patients (19%) had a 
lymphocyte count ranging between 1 and 1.5 × 103 cells/
µL with a median of 1.19 [1.10–1.30] × 103 cells/µL; 278 
patients (37%) had a lymphocyte count ranging between 
0.5 and 1 × 103 cells/µL with a median of 0.72 [0.61–0.84] 
Page 4 of 10Adrie et al. Ann. Intensive Care  (2017) 7:30 
×  103 cells/µL; 185 patients (24%) had a lymphocyte 
count lower than 0.5 × 103 cells/µL with a median of 0.34 
[0.24–0.43] × 103 cells/µL.
Among the total of 174 (24%) ICU-acquired infections, 
pneumonia was diagnosed in 113 (64.9%) patients, bacte-
remia in 37 (21.3%) and catheter-associated infection in 
36 (20.7%). In 13 patients, 2 sites of infection were diag-
nosed the same day. Enterobacteriaceae bacteria were 
the most frequent pathogens isolated, followed by Pseu-
domonas spp. and Staphylococcus aureus (Tables 2, 3).
There were no relationships between the lymphocyte 
count and the SOFA score, and between the delta of the 
SOFA score and the variations in the lymphocyte counts. 
This result is consistent with our results about the inde-
pendent role of immune paralysis and organ failures.
Risk of ICU‑acquired infection
Comparisons between patients with ICU-acquired infec-
tion and the others are shown in Table 1. The final logis-
tic model used to calculate propensity score is given in 
Additional file  1: Table E1. The cumulative incidence 
curve of ICU-acquired infection is shown in Fig. 2a.
Sub-distribution hazard ratios (sHRs) of ICU-acquired 
infection were significant for abnormal values at admis-
sion (Table  4), with no difference between subnormal 
and very low lymphocyte counts. The absence of relevant 
increase in the lymphocyte count at day 3 was associ-
ated with an increased risk of developing an infection 
(sHR of 1.37 [1.12–1.67], p = 0.002) (Fig. 2b). The inter-
action term between baseline lymphocyte count and 
lymphocyte increase at day 3 was not significant. Impor-
tantly, the onset of ICU-acquired infection was associ-
ated with an increased day-28 mortality (p < 0.001).
Risk of 28‑day mortality
Comparisons between patients’ dead in ICU and others 
are shown in Table 1, using the final logistic model used 
to calculate propensity score (Additional file 1: Table E2). 
The incidences of 28-day mortality according to baseline 
lymphocyte count and its evolution at day 3 are shown in 
Table 5. The baseline count of lymphocyte had no impact 
on the 28-day mortality in ICU. However, the decrease 
or the non-significant increase on day 3 was significantly 
associated with the death in ICU [sHR of 1.67 [1.37–
2.03], p < 0.0001 (Table  5)]. The cumulative incidence 
curve of death according to the evolution of lymphocyte 
count is represented in Fig. 2c.
Discussion
To our knowledge, our study is the first large cohort 
study which evaluated the relation between the baseline 
lymphocyte count and its evolution at day 3, and the risk 
of ICU-acquired infection and death in patients admitted 
in ICU with sustained hypotension. We demonstrated 
the significant independent prognostic impact of a low 
lymphocyte count at baseline on the risk to develop an 
ICU-acquired infection. A persisting lymphopenia or a 
non-significant increase at day 3 is associated with a risk 
to develop a nosocomial infection and with increased 
28-day mortality (Additional file 1).
Fig. 1 Flowchart
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Acute critical ill patients, particularly in case of sepsis, 
often present signs of systemic inflammatory response 
syndrome (SIRS) which could be related to pro-inflam-
matory response. Beside this pro-inflammatory response, 
an anti-inflammatory response occurs. In these patients, 
several studies showed increased secretion of anti-
inflammatory cytokines, e.g., IL-10, and decreased 
activation of immunity cells, e.g., monocytes [20, 21]. 
Thus, the immune response can display various profiles: 
combined anti- and pro-inflammatory response; anti-
inflammatory response; or global immune depression. 
This syndrome of acquired deficiency of immune sys-
tem is called the post-aggressive immunosuppression or 
compensatory anti-inflammatory response syndrome 
(CARS) [3, 4]. This secondarily impaired immunity has 
been described for decades [9]; several studies correlated 
it with poor outcome [5–7, 22]. This could explain the 
onset of nosocomial infections with opportunistic micro-
organism in septic patients, e.g., viral reactivation or fun-
gal infection [23–25].
CARS involves both the innate and adaptive parts of 
immune system. It affects different cells involved in the 
Table 1 Patients’ characteristics at admission
Data are expressed as number (%) or median [interquartile]. ICU: intensive care unit; SAPS II: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure 
Assessment. Of note, in some cases, septic shock was not the cause of admission in ICU, but developed within the first hours of ICU admission
Variable Population
N = 753
No ICU‑acquired  
infection (N = 579)
With ICU‑acquired  






Age 68 [56–78] 67.6 [56–78] 69 [55–77] 0.4106 66.5 [55–77] 71.5 [59–79] 0.02
Men 467 (62) 342 (59) 125 (72) 0.0023 359 (61) 108 (67) 0.13
Length of stay (days) 9 [6–18] 7 [5–13] 23 [14–37] <.0001 9 [5–19] 10 [7–17] 0.18
Center
 A 501 (66.5) 402 (69) 99 (57) 0.0030 406 (69) 95 (59.0) 0.002
 B 105 (14) 80 (14) 25 (14) 86 (14) 19 (12)
 C 35 (4.6) 21 (3.6) 14 (8.0) 27 (4.6) 8 (5.0)
 D 112 (15) 76 (13) 36 (21) 73 (12) 39 (24)
Admission category 0.7400 0.003
 Medical 596 (79) 457 (19) 139 (80) 454 (77) 142 (88)
 Unscheduled surgery 104 (14) 79 (14) 25 (14) 94 (16) 10 (6)
 Scheduled surgery 53 (7) 43 (7) 10 (6) 44 (7) 9 (6)
Co‑morbidities (Knaus definitions)
 Chronic hepatic failure 45 (6.0) 41 (7) 4 (2.3) 0.0196 30 (5) 15 (9) 0.044
 Chronic cardiovascular failure 101 (13.4) 70 (12) 31 (18) 0.0519 70 (12) 31 (19) 0.014
 Chronic respiratory failure 157 (20.8) 120 (21) 37 (21) 0.8780 126 (21) 31 (19) 0.57
 Chronic renal failure 61 (8.1) 47 (8.1) 14 (8.0) 0.9758 44 (7.4) 17 (10.6) 0.19
 Immunosuppression 69 (9.2) 54 (9.3) 15 (8.6) 0.7772 59 (10.0) 10 (6.2) 0.14
Long‑term corticosteroids use 24 (3.2) 19 (3.3) 5 (2.9) 0.7882 20 (3.4) 4 (2.5) 0.57
History of chemotherapy 40 (5.3) 31 (5) 9 (5.2) 0.9254 31 (5) 9 (5) 0.86
Main reason of admission
 Coma 106 (14) 81 (14) 25 (14) 0.8999 81 (14) 25 (15) 0.55
 Acute respiratory failure 211 (28.0) 150 (26) 61 (35) 0.0184 164 (27.7) 47 (29) 0.71
 Septic shock 154 (20.4) 123 (21) 31 (18) 0.3257 121 (20) 33 (20) 0.99
 Cardiogenic shock 39 (5) 14 (4) 15 (8) 0.0195 22 (4) 17 (11) 0.0005
 Hemorrhage shock 50 (6.6) 40 (7) 10 (6) 0.5895 43 (7) 7 (4) 0.19
 Multi‑organ failure 21 (3) 11 (2) 10 (6) 0.0069 14 (2) 7 (4) 0.17
 Shock (other) 27 (3.6) 23 (4) 4 (2) 0.2978 21 (3.5) 6 (4) 0.91
 Other 145 (19) 127 (22) 18 (10) 0.0007 126 (21) 19 (12) 0.007
SAPS II score 49 [37–60] 48 [3–59] 51 [40–62] 0.0374 47 [36–57] 57 [46–66] <0.0001
SOFA score 8 [5–11] 8 [5–11] 10 [7–12] <.0001 7.5 [5–11] 10 [7–12] <0.0001
Cardiovascular SOFA score (>2) 462 (61) 333 (57) 129 (74) <.0001 333 (56) 129 (80) <0.0001
Mechanical ventilation 559 (74) 411 (71) 148 (85) 0.0002 422 (71) 137 (85) 0.0004
Antibiotic day 1 or 2 581 (77) 448 (77) 133 (76) 0.80 455 (78) 126 (78) 0.71
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innate immune system, such as polymorphonuclear neu-
trophils, dendritic cells, and monocytes. The link with a 
poor outcome was demonstrated in several studies [4, 
26]. Monocytes dysfunction is now evaluated by a clini-
cally validated surrogate marker: mHLA-DR expression 
[4, 27]. While biological testing of mHLA-DR expression 
is standardized [10] and then could offer a well-recog-
nized biological test to select patients who would benefit 
of immune-adjuvant therapy, this test is not yet general-
ized in clinical practice.
The acquired immunity cells such as lymphocytes are 
also affected. Lymphocytes, particularly T-cells subset, 
are a cornerstone of the adaptive response to aggres-
sions. An acquired or congenital lymphocyte deficiency 
increases the risk of infection and of death. CARS is 
correlated with lymphocyte function alteration, which 
has been described for 30  years. Function alteration is 
reflected by a decreased production of pro-inflamma-
tory cytokines, such as IL-2, an increased production of 
anti-inflammatory cytokines, such as IL-10, an increased 
expression on cells membrane of inhibitory receptor such 
as programmed cell death-1, and a decreased expression 
of T-cell receptor repertoire diversity [27–31]. While our 
understanding of the mechanism of lymphocyte altera-
tion during sepsis progresses, the link with patient’s 
prognosis is not always established.
An increased apoptosis was described in patients [12, 
22]. Various pathways seem to be involved in the lym-
phocyte apoptosis in case of sepsis: an extrinsic pathway, 
mediated by the caspase-8, and an intrinsic pathway, 
mediated by the caspase-9 [10, 22]. In the study of Le 
Tulzo et  al. [22], the magnitude of apoptosis was corre-
lated with the persistence of multi-organ dysfunctions, 
duration of mechanical ventilation, and death. The corre-
lation between the quantitative alteration of lymphocyte 
and a poor outcome was shown in two studies involv-
ing children [12, 32, 33]. In 21 adult patients with septic 
shock, Venet et al. [12] also described a median lympho-
cyte count within the first 24  h following admission for 
septic shock close to our results (0.5–0.7 × 103 cells/µL). 
Altered lymphocyte function with recombinant human 
IL-7 or anti-programmed cell death-1 antibody may be 
promising targets for future clinical studies [27].
In a retrospective study of bacteremic patients, an asso-
ciation was observed between persistent lymphopenia 
(defined as below of 0.6 × 103 cells/µLon the fourth day) 
with the 28-day mortality (primary endpoint), 1-year 
mortality, and subsequent hospital infection [15]. How-
ever, the low baseline total lymphocyte count (≤0.6 × 103 
cells/µL) was not associated with any of them, conversely 
to what we observed in our study. This difference may be 
due to the lymphopenia threshold definitions, and also to 
the case mix, as we included all patients with sustained 
hypotension, whether or not they had sepsis and/or bac-
teremia. As a matter of fact, we included all patients with 
an unstable hemodynamic status, in order to take into 
account the severity of patient as a promoter of CARS. 
Indeed, dysfunction of immune system was observed 
not only in septic patients, but also in post-traumatic or 
severely burned patients [34–37].
Although our study did not provide information on the 
link between the lymphocyte count and the qualitative 
alteration of lymphocyte function, it is the first one that 
demonstrated in a large cohort of patients, the impact 
of a low lymphocyte count at ICU admission and of its 
persistence on the risk to develop an ICU-acquired infec-
tion and of increased mortality. The interaction between 
Table 2 Description of  ICU-acquired infection related 
to site of infection and time to event
Data are expressed as number (%) or median [interquartile]
No (%) Time to event  
(median [IQ]) or  
days of event
Total 174 8
Pneumonia 113 (64.9) 10 [6–15]
Bacteremia 37 (21.3) 8 [6–13]
Catheter‑associated infection 36 (20.7) 8 [5–13]
Pneumonia with bacteremia 6 (3.4) 11.5 [7–23]
Catheter infection with bacteremia 3 (1.7) 13 [7–22]
Pneumonia with catheter‑associated  
infection
3 (1.7) 13 [4–14]
Table 3 Description of  ICU-acquired infection related 
to site of  infection and microorganism (percentage of the 
total of pathogens isolated in a site)
Data are expressed as number (%) or median [interquartile]. MDR: multi-
drug-resistant, including methicillin-resistant Staphylococcus aureus, 
Enterobacteriaceae resistant to third-generation cephalosporins, Pseudomonas 
aeruginosa resistant to ticarcillin and/or imipenem and/or ceftazidime, 
Stenotrophomonas maltophilia, Burkholderia cepacia, and Acinetobacter 
baumannii. GPB; Gram-positive bacteria, GNB; Gram-negative Bacteria; 
non-fermenting GNB (Pseudomonas spp., Acinetobacter baumannii, 









21 (18.6) 6 (16.2) 3 (8.3)
Coagulase‑negative 
Staphylococci
8 (7.1) 5 (13.5) 9 (25.0)
Other GPB 16 (14.2) 9 (24.3) 8 (22.2)
Fermenting GNP 46 (40.7) 13 (35.1) 14 (38.9)
Non‑fermenting GNP 40 (35.4) 6 (16.2) 7 (19.4)
Anaerobes 1 (0.9) 1 (2.7) 0
Fungi 5 (4.4) 5 (13.5) 1 (2.8)
Polymicrobial 21 (18.6) 8 (21.6) 5 (13.9)
MDR pathogens 47 (45.6) 10 (27.0) 9 (25.0)
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Fig. 2 Cumulative incidence curves of ICU‑acquired infection a according to baseline lymphocyte count categorized in 4 classes; cumulative inci‑
dence curve of ICU‑acquired infection (b) and incidence curve of death (c) according to the increase from baseline of the lymphocyte count at day 
3 (increase in lymphocyte count was considered significant if greater than 0.2 × 103 cells/µL). Numbers below each figure represent the number of 
patients still at risk of event at a particular time point. No patient were lost to follow‑up at day 28
Table 4 Results of the sub-distribution Hazard ratio (sHR) of baseline lymphocyte count and its evolution at day 3 for the 
risk of ICU-acquired infection (adjusted with the covariates used in the propensity score of acquiring a nosocomial infec-
tion before day 28 using an IPTW estimator; see Additional file 2)
Variables sHR IC‑95 p value
Baseline lymphocyte count categorized in 4 classes 0.001
 Normal value ≥1.5 × 103 cells/µL Reference – –
 Subnormal class (<1.5 and ≥ 1 × 103 cells/µL) 1.60 1.24 2.08 0.0004
 Low class (<1 × 103 cells/µL and ≥0.5 × 103 cells/µL) 1.43 1.12 1.85 0.004
 Very low class (<0.5 × 103 cells/µL) 1.63 1.23 2.15 0.0006
 Non‑significant increase (below 0.2 × 103 cells/µL) at day 3 and abnormal value 1.37 1.12 1.67 0.002
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the lymphocyte count at baseline and its evolution found 
in our study could reflect the persistent status of post-
aggressive immunosuppression. Of course, our study did 
not preclude the absence of added prognostic value of the 
lymphocyte subsets, which has already been reported in 
the literature [22, 28, 38]; however, it highlights that the 
routinely measured total lymphocyte count may be taken 
into account. Indeed, the total lymphocyte count is sim-
ple to evaluate, without any special skill or laboratory 
equipment. However, further studies are warranted to 
figure out whether or not functional new markers would 
add more information that plain absolute lymphocyte 
counts.
Case mix varied between centers, which may explain 
significant differences between numbers of exams per-
formed and mean lymphocyte counts between centers. 
However, we did not unmask heterogeneity between 
prognostic impacts of lymphocyte alterations between 
centers. We cannot make any causative relationship 
between mortality and ICU-acquired infection with low 
lymphocyte count, as they may all be related to the dis-
ease severity. Also, we do have any data on the immu-
noresponse and the anergy–apoptosis of this lymphocyte 
in general and lymphopenia in particular, as it could be 
expected from a retrospective study that requires a pro-
spective confirmation using the functional activities of 
the different lymphocytes involved in the inflammation 
processes.
Conclusion
A large cohort of ICU patients with shock at admission, 
we demonstrated the independent impact of a low base-
line lymphocyte count and its non-relevant increase at 
day 3 with the risk of ICU-acquired infection and, for 
persistent lymphopenia, its impact on 28-day mortality. 
Total lymphocyte count appears as a simple and routine 
marker of immune dysfunction, and might be useful for 
selecting patients that could benefit of potential immune-
adjuvant therapies [27].
Abbreviations
sHR: sub‑distribution hazard ratio; ICU: intensive care unit; CARS: compensa‑
tory anti‑inflammatory response syndrome, IL‑6, interleukin‑6; TNF‑α: tumor 
nuclear factor; SAPS II: Simplified Acute Physiology Score; SOFA: Sequential 
Organ Failure Assessment; GCS: Glasgow Coma Scale; CLL: chronic lympho‑
cytic leukemia; HIV: infection with the human immunodeficiency virus; HELICS: 
Hospital in Europe Link for Infection Control through Surveillance project; BAL: 
broncho‑alveolar lavage; CFU: coloning‑forming unit; SIRS: systemic inflam‑
matory response syndrome; IPTW: inverse probability of treatment weighted; 
IL‑10: interleukin‑10; mHLA‑DR expression: monocytes dendritic cell HLA‑D 
expression.
Authors’ contributions
JFT, ML, CA conceived and designed the study, and was involved in drafting 
the manuscript and provided research funding. RS, BS, JCC, MGO, CS collected 
data and critically revised the manuscript. SR collected and analyzed data, 
performed statistical analysis, and drafted and critically revised the manu‑
script. All authors gave final approval for manuscript publication and agree to 
be accountable for all aspects of this work. All authors read and approved the 
final manuscript.
Author details
1 Physiology Department, Cochin University Hospital, AP‑HP, Paris Descartes 
University, 27 rue du Faubourg Saint Jacques, 75014 Paris, France. 2 Polyvalent 
ICU, Delafontaine Hospital, Saint‑Denis, France. 3 Medical ICU, Grenoble 1 Uni‑
versity, Albert Michallon Hospital, Grenoble, France. 4 Medical and Infectious 
Diseases ICU, Bichat University Hospital, AP‑HP, Paris, France. 5 Clermont‑Fer‑
rand University, Medical ICU, Gabriel Montpied Hospital, Clermont‑Ferrand, 
France. 6 UMR 1137 IAME Inserm‑ Paris Diderot University, 75018 Paris, France. 
7 Polyvalent ICU, St Joseph Hospital, Paris, France. 
Acknowledgements
The authors thank Celine Feger, MD (EMIBiotech) for her editorial assistance.
The study was set up and conducted by the Outcomerea network. The 
members of the OUTCOMEREA Study Group are listed in “Appendix".
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Data and material are available on the website “lymphocyte_data‑set”
Additional files
Additional file 1. Lymphocyte_data‑set.
Additional file 2. Details on the model fitting propensity score used.
Table 5 Results of the sub-distribution Hazard ratio (sHR) of baseline lymphocyte count and its evolution at day 3 for the 
risk of 28-day ICU mortality (adjusted with the covariates used in the propensity score of dying before day 28 using an 
IPTW estimator; see Additional file 2)
Variables sHR IC‑95 p value
Baseline lymphocyte count categorized in 4 classes 0.15
 Normal value ≥1.5 × 103 cells/µL Reference – –
 Subnormal class (<1.5 and ≥ 1 × 103 cells/µL) 0.84 0.658 1.08 0.176
 Low class (<1 × 103 cells/µL and ≥0.5 × 103 cells/µL) 1.09 0.891 1.36 0.377
 Very low class (<0.5 × 103 cells/µL) 0.99 0.773 1.28 0.969
 Non‑significant increase (below 0.2 × 103 cells/µL) at day 3 and abnormal value 1.67 1.37 2.03 <0.0001
Page 9 of 10Adrie et al. Ann. Intensive Care  (2017) 7:30 
Ethical approval
This study was approved by our institutional review board (CECIC Clermont‑
Ferrand—IRB n°5891; Ref: 2007–2016), which waived the need for signed 
informed consent of the participants, in accordance with French legislation on 
non‑interventional studies. . However, the patients and their next of kin were 
asked whether they were willing to participate in the database, and none 
declined participation.
Funding
The study was funded by the non‑profit OutcomeRea network. The Outcom‑
eRea network takes full administrative responsibility for data management, 
analysis, and interpretation and for manuscript preparation, review, and 
approval.
Appendix: Members of the OUTCOMEREA study 
group
Scientific committee
Jean-François Timsit (Hôpital Bichat, Paris and INSERM 
U823, Grenoble, France), Elie Azoulay (Medical ICU, 
Hôpital Saint Louis, Paris, France), Yves Cohen (ICU, 
Hôpital Avicenne, Bobigny, France), Maïté Garrouste-
Orgeas (ICU Hôpital Saint-Joseph, Paris, France), Lilia 
Soufir (ICU, Hôpital Saint-Joseph, Paris, France), Jean-
Ralph Zahar (Microbiology Department, Hôpital Necker, 
Paris, France), Christophe Adrie (ICU, Hôpital Cochin, 
Paris, France), Michael Darmon (Medical ICU, Univer-
sity hospital St Etienne, France), Corinne Alberti (Rob-
ert Debré Hospital, Paris France) and Christophe Clec’h 
(ICU, Hôpital Avicenne, Bobigny, and INSERM U823, 
Grenoble, France).
Biostatistical and informatics expertise
Jean-Francois Timsit (Hôpital Albert Michallon and 
Integrated Research Center U823, Grenoble, France), 
Corinne Alberti (Medical Computer Sciences and Biosta-
tistics Department, Robert Debré, Paris, France), Adrien 
Français (Integrated Research Center U823, Grenoble, 
France), Aurélien Vesin (Integrated Research Center 
U823, Grenoble, France), Stephane Ruckly INSERM 
U823, Grenoble, France), Christophe Clec’h (ICU, Hôpi-
tal Avicenne, Bobigny, and INSERM U823, Grenoble, 
France), Frederik Lecorre (Supelec, France), and Didier 
Nakache (Conservatoire National des Arts et Métiers, 
Paris, France), Aurélien Vannieuwenhuyze (Tourcoing, 
France).
Investigators of the Outcomerea database
Christophe Adrie (ICU, Hôpital Delafontaine, Saint 
Denis, France and Physiology, Hôpital Cochin, Paris, 
France), Bernard Allaouchiche (Surgical ICU, Edouard 
Herriot Hôpital, Lyon), Claire Ara-Somohano (CHU A 
Michallon, Grenoble, France), Laurent Argault (medi-
cal ICU Edouard Herriot Hôpital, Lyon), Agnès Bona-
dona (CHU A Michallon, Grenoble, France), Caroline 
Bornstain (ICU, Hôpital de Montfermeil, France), Lila 
Bouadma (ICU, hôpital Bichat Claude-Bernard, Paris, 
France), Alexandre Boyer (ICU, Hôpital Pellegrin, Bor-
deaux, France), Christine Cheval (SICU, Hôpital Saint-
Joseph, Paris, France), Jean-Pierre Colin (ICU, Hôpital 
de Dourdan, Dourdan, France), Michael Darmon (ICU, 
CHU Saint Etienne), Anne-Sylvie Dumenil (Hôpital 
Antoine Béclère, Clamart France), Adrien Descorps-
Declere (Hôpital Antoine Béclère, Clamart France), 
Jean-Philippe Fosse (ICU, Hôpital Avicenne, Bobigny, 
France), Rebecca Hamidfar-Roy (CHU A Michallon, Gre-
noble, France), Samir Jamali (ICU, Hôpital de Dourdan, 
Dourdan, France), Hatem Khallel (ICU, Cayenne Gen-
eral Hospital), Christian Laplace (ICU, Hôpital Kremlin-
Bicêtre, Bicêtre, France), Alexandre Lautrette (ICU, CHU 
G Montpied, Clermont-Ferrand), Thierry Lazard (ICU, 
Hôpital de la Croix Saint-Simon, Paris, France), Eric Le 
Miere (ICU, Hôpital Louis Mourier, Colombes, France), 
Maxime Lugosi (CHU A Michallon, Grenoble, France), 
Guillaume Marcotte (surgical ICU, Edouard Herriot 
Hôpital, Lyon), Laurent Montesino (ICU, Hôpital Bichat, 
Paris, France), Bruno Mourvillier (ICU, Hôpital Bichat, 
France), Benoît Misset (ICU, Hôpital Saint-Joseph, Paris, 
France), Delphine Moreau (ICU, Hôpital Saint-Louis, 
Paris, France), Etienne Pigné (ICU, Hôpital Louis Mour-
ier, Colombes, France), Stéphane Ruckly (Integrated 
Research Center U823, Grenoble, France), Bertrand 
Souweine (ICU, CHU G Montpied, Clermont-Ferrand), 
Carole Schwebel (CHU A Michallon, Grenoble, France), 
Gilles Troché (Hôpital Antoine, Béclère, Clamart 
France), Marie Thuong (ICU, Pontoise, France), Guil-
laume Thierry (ICU, Hôpital Saint-Louis, Paris, France), 
Dany Toledano (CH Gonnesse, France), and EricVanta-
lon (SICU, Hôpital Saint-Joseph, Paris, France).
Study monitors
Caroline Tournegros, Loïc Ferrand, Nadira Kaddour, 
Boris Berthe, Kaouttar Mellouk, Veronique Deiler, Kelly 
Tiercelet, Sophie Letrou, Igor Théodose, and Julien 
Fournier.
Received: 21 July 2016   Accepted: 4 February 2017
References
 1. Buckley RH. Primary immunodeficiency diseases due to defects in lym‑
phocytes. N Eng J Med. 2000;343:1313–24.
 2. Levy JA. Infection by human immunodeficiency virus–CD4 is not enough. 
N Eng J Med. 1996;335:1528–30.
 3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Eng 
J Med. 2003;348:138–50.
 4. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunc‑
tions in the septic patient: a new skin for the old ceremony. Mol Med. 
2008;14:64–78.
Page 10 of 10Adrie et al. Ann. Intensive Care  (2017) 7:30 
 5. Delano MJ, Thayer T, Gabrilovich S, Kelly‑Scumpia KM, Winfield RD, 
Scumpia PO, et al. Sepsis induces early alterations in innate immunity that 
impact mortality to secondary infection. J Immuno. 2011;186:195–202.
 6. Grimaldi D, Louis S, Pene F, Sirgo G, Rousseau C, Claessens YE, et al. Pro‑
found and persistent decrease of circulating dendritic cells is associated 
with ICU‑acquired infection in patients with septic shock. Intensive Care 
Med. 2011;37:1438–46.
 7. Lukaszewicz AC, Grienay M, Resche‑Rigon M, Pirracchio R, Faivre V, 
Boval B, et al. Monocytic HLA‑DR expression in intensive care patients: 
interest for prognosis and secondary infection prediction. Crit Care Med. 
2009;37:2746–52.
 8. Guisset O, Dilhuydy MS, Thiebaut R, Lefevre J, Camou F, Sarrat A, et al. 
Decrease in circulating dendritic cells predicts fatal outcome in septic 
shock. Intensive Care Med. 2007;33:148–52.
 9. Christou NV, Meakins JL, Gordon J, Yee J, Hassan‑Zahraee M, Nohr CW, 
et al. The delayed hypersensitivity response and host resistance in surgi‑
cal patients. 20 years later. Ann Surg. 1995;222:534–46.
 10. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and 
inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.
 11. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, 
et al. Sepsis‑induced apoptosis causes progressive profound depletion of 
B and CD4+ T lymphocytes in humans. J Immunol. 2001;166:6952–63.
 12. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, et al. Early 
assessment of leukocyte alterations at diagnosis of septic shock. Shock. 
2010;34:358–63.
 13. de Jager CP, van Wijk PT, Mathoera RB, de Jongh‑Leuvenink J, van der 
Poll T, Wever PC. Lymphocytopenia and neutrophil‑lymphocyte count 
ratio predict bacteremia better than conventional infection markers in an 
emergency care unit. Crit Care. 2010;14:R192.
 14. Lewis RT, Klein H. Risk factors in postoperative sepsis: significance of 
preoperative lymphocytopenia. J Surg Res. 1979;26:365–71.
 15. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss 
RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. 
Shock. 2014;42:383–91.
 16. Mertens R, Van Den Berg JM, Fabry J, Jepsen OB. HELICS: a European 
project to standardise the surveillance of hospital acquired infection, 
1994‑1995. Euro surveillance. 1996;1:28–30.
 17. Gayat E, Pirracchio R, Resche‑Rigon M, Mebazaa A, Mary JY, Porcher R. 
Propensity scores in intensive care and anaesthesiology literature: a 
systematic review. Intensive Care Med. 2010;36:1993–2003.
 18. Bailly S, Pirracchio R, Timsit JF. What’s new in the quantification of causal 
effects from longitudinal cohort studies: a brief introduction to marginal 
structural models for intensivists. Intensive Care Med. 2016;42:576–9.
 19. Lunceford JK, Davidian M. Stratification and weighting via the propensity 
score in estimation of causal treatment effects: a comparative study. Stat 
Med. 2004;23:2937–60.
 20. Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, et al. 
Downregulation of CD40 ligand response in monocytes from sepsis 
patients. Clin Vaccine Immuno. 2008;15:1851–8.
 21. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich 
M. Anti‑inflammatory cytokine profile and mortality in febrile patients. 
Lancet. 1998;351:950–3.
 22. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, et al. Early 
circulating lymphocyte apoptosis in human septic shock is associated 
with poor outcome. Shock. 2002;18:487–94.
 23. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, Allardet‑Servent J, et al. 
Active cytomegalovirus infection is common in mechanically ventilated 
medical intensive care unit patients. Crit Care Med. 2009;37:1850–7.
 24. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immu‑
noparalysis as a cause for invasive aspergillosis? Intensive Care Med. 
2003;29:2068–71.
 25. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, 
et al. Cytomegalovirus reactivation in critically ill immunocompetent 
patients. JAMA. 2008;300:413–22.
 26. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset 
of neutrophils in human systemic inflammation inhibits T cell responses 
through Mac‑1. J Clin Invest. 2012;122:327–36.
 27. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring 
the immune response in sepsis: a rational approach to administration of 
immunoadjuvant therapies. Curr Opin Immuno. 2013;25:477–83.
 28. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. 
Immunosuppression in patients who die of sepsis and multiple organ 
failure. JAMA. 2011;306:2594–605.
 29. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, et al. Pro‑
grammed death‑1 levels correlate with increased mortality, nosocomial 
infection and immune dysfunctions in septic shock patients. Crit Care. 
2011;15:R99.
 30. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a 
novel understanding of the disorder and a new therapeutic approach. 
Lancet Inf Dis. 2013;13:260–8.
 31. Venet F, Filipe‑Santos O, Lepape A, Malcus C, Poitevin‑Later F, Grives A, 
et al. Decreased T‑cell repertoire diversity in sepsis: a preliminary study. 
Critl Care Med. 2013;41:111–9.
 32. Adamski JK, Arkwright PD, Will AM, Patel L. Transient lymphopenia in 
acutely unwell young infants. Arch Dis Child. 2002;86:200–1.
 33. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, 
lymphoid depletion, and hypoprolactinemia in children with nosocomial 
sepsis and multiple organ failure. J Immunol. 2005;174:3765–72.
 34. Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C, 
et al. Lack of recovery in monocyte human leukocyte antigen‑DR expres‑
sion is independently associated with the development of sepsis after 
major trauma. Crit Care. 2010;14:R208.
 35. Pellegrini JD, De AK, Kodys K, Puyana JC, Furse RK, Miller‑Graziano C. Rela‑
tionships between T lymphocyte apoptosis and anergy following trauma. 
J Surg Res. 2000;88:200–6.
 36. Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Denny T, et al. 
Depressed interleukin‑12‑producing activity by monocytes correlates 
with adverse clinical course and a shift toward Th2‑type lympho‑
cyte pattern in severely injured male trauma patients. Crit Care Med. 
2003;31:1722–9.
 37. Venet F, Tissot S, Debard AL, Faudot C, Crampe C, Pachot A, et al. 
Decreased monocyte human leukocyte antigen‑DR expression after 
severe burn injury: correlation with severity and secondary septic shock. 
Crit Care Med. 2007;35:1910–7.
 38. Boomer JS, Shuherk‑Shaffer J, Hotchkiss RS, Green JM. A prospective 
analysis of lymphocyte phenotype and function over the course of acute 
sepsis. Crit Care. 2012;16:R112.
